Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
3
75%

Phase Distribution

0

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 23 (100.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials
Showing 4 of 4
completed

ToleroMune Ragweed Follow up Study

NCT01448603
completedphase_2

ToleroMune Ragweed Exposure Chamber Study

NCT01198613
completedphase_2

Identification of Potential Biomarkers of Response to Peptide Immunotherapy for Ragweed Allergy

NCT01361412
completedphase_2

Safety of ToleroMune Ragweed to Treat Ragweed Allergy in Ragweed Allergic Subjects With Rhinoconjunctivitis

NCT00878774

Clinical Trials (4)

Showing 4 of 4 trials
NCT01448603

ToleroMune Ragweed Follow up Study

Completed
NCT01198613Phase 2

ToleroMune Ragweed Exposure Chamber Study

Completed
NCT01361412Phase 2

Identification of Potential Biomarkers of Response to Peptide Immunotherapy for Ragweed Allergy

Completed
NCT00878774Phase 2

Safety of ToleroMune Ragweed to Treat Ragweed Allergy in Ragweed Allergic Subjects With Rhinoconjunctivitis

Completed

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4